Statewide Collaborative to Improve Venous Thromboembolism Prophylaxis after Abdominopelvic Cancer Surgery

Kimberly B. Golisch, MD¹; Casey M. Silver MD¹; Ying Shan, MS¹; Andres Guerra MD¹; Lauren M. Janczewski MD¹, Jeanette Chung PhD²; Brianna D'Orazio, MPH²; Julie Johnson, PhD¹; Michael F. Mcgee MD³;

David D. Odell MD MS¹; Anthony D. Yang MD MS²; Karl Y. Bilimoria, MD, MS²: Ryan P. Merkow MD MS⁴

1. Northwestern Quality Improvement, Research, and Education in Surgery (NQUIRES) 2. Indiana University of Michigan Department of Surgery 4. University of Chicago Department of Surgery


Background



Venous thromboembolism (VTE) is a leading cause of preventable morbidity and mortality after abdominopelvic cancer surgery^{1,2}. Adherence to guideline-recommended post-discharge VTE chemoprophylaxis remains low³.

Research Objectives

Illinois Surgical Quality Improvement Collaborative (ISQIC) implemented a post-discharge VTE process measure in 2016.



- 1. Evaluate post-discharge VTE chemoprophylaxis prescription adherence rates
- 2. Identify variation at the patient and hospital levels for the process measure

Methods

Multi-institutional Prospective Observational Cohort Study

NSQIP database and ISQIC process-measure database

Inclusion criteria:

- Patients who underwent abdominopelvic resection for malignancy
- Surgery performed in the state of Illinois at an ISQIC enrolled hospital
- Surgeries performed by general surgeons, urologists, or gynecologists

Exclusion criteria:


- Outpatient surgery
- Patients with contraindications to prophylactic anticoagulation
- Patients who suffered inpatient death

Phase 1 33 hospitals Start: April-Aug 2016

Phase 2
31 hospitals
*Optional Sept 2017


Phase 3
16 hospitals
End: April-July 2019

Post-Discharge VTE Adherence Rates



Overall, increase in adherence rates over the three phases

Post-Discharge VTE Adherence by Hospital Site



Results

	Pos	la (n=1367)	Vac (n=2145)	OR CI
Λσο	IN	lo (n=1367)	Yes (n=2145)	OR, CI
Age <44		77	112	Ref
45-64				
	594 (41.6)		830 (58.4)	1.00, (0.73-1.39)
65-74 74-84		368 (36.7) 244 (36.4)	635 (63.3)	1.22, (0.88-1.70)
>85		84 (37.3)	427 (63.6) 141 (62.7)	1.38, (0.98, 1.95) 1.46, (0.97-2.22)
Sex		64 (37.3)	141 (02.7)	1.40, (0.97-2.22)
Male		750 (42.4)	1020 (57.6)	Ref
Female		617 (35.4)	1125 (64.6)	1.03, (0.89-1.21)
BMI			222 (0 113)	
<18.5	36 (39.1)		56 (60.9)	1.00, (0.63-1.59)
18.5-24.9	349 (37.8)		574 (62.2)	Ref
25-29.9	484 (41.7)		677 (58.3)	0.87, (0.72-1.08)
>30		498 (37.3)	838 (62.7)	0.88, (0.71-1.08)
Race/Ethnicity				
White	1100 (39.5)		1688 (60.5)	Ref
Black	152 (37.1)		258 (62.9)	1.16, (0.92-1.45)
Asian	55 (42.3)		75 (57.7)	0.85, (0.59-1.24)
Other/Unknown	60 (32.6)		124 (67.4)	1.29, (0.92-1.80)
Current Smoker				
Yes	182 (39.0)		285 (61.0)	1.08, (0.88-1.34)
No	1185 (38.9)		1860 (61.1)	Ref
Procedure type				
Colorectal		959 (44.1)	1215 (55.9)	Ref
Hepato-pancreatico-biliary		101 (29.4)	243 (70.6)	1.97, (1.53-2.54)
Urologic		208 (41.9)	289 (58.1)	1.13, (0.92-1.38)
Gynecologic		64 (16.7)	319 (83.3)	3.92, (2.92-5.27)

- No associations between patient demographic characteristics and passing the measure when adjusting for confounders
- More likely prescribed post-discharge chemoprophylaxis if under went hepatopancreatico-biliary or gynecologic surgery compared to colorectal surgery
- Significant hospital level variability

Limitations

- NSQIP contains hospitals participating in ISQIC or other quality improvement programs
- Implementation changed to optional mid-way through study
- Characteristics were not evaluated between time points, only across all 3 phases

Conclusions

- Implementation of a post-discharge VTE QIP was associated with an increase in rate of process measure adherence
- Future work to focus on specific hospital-level differences and interventions

Referen

- 1. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged thromboprophylaxis with low molecular weight
- heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2009(1):CD004318.
- 2. Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011;117:1334-49.
- 3. Geahchan N, Basile M, Tohmeh M, registry D. Venous thromboembolism prophylaxis in patients undergoing abdominal and pelvic cancer surgery: adherence and compliance to ACCP guidelines in DIONYS registry. Springerplus. 2016;5(1):1541.



M Northwestern Medicine®

Feinberg School of Medicine